Long-Acting Insulin Dosing After DKA Resolution
After DKA has resolved, initiate long-acting basal insulin at 50% of the calculated total daily insulin dose (TDD), with the TDD calculated as 0.2-0.5 U/kg based on patient characteristics, and continue IV insulin for 1-2 hours after the first subcutaneous dose to prevent rebound hyperglycemia.
Calculating the Total Daily Dose
The Endocrine Society guidelines provide a weight-based approach for calculating TDD 1:
0.2-0.3 U/kg/day for patients who are:
- Age ≥70 years, OR
- GFR <60 mL/min
0.4 U/kg/day for patients with blood glucose 140-200 mg/dL (7.8-11.1 mmol/L)
0.5 U/kg/day for patients with blood glucose 201-400 mg/dL (11.2-22.2 mmol/L)
Distribution of Insulin Doses
Distribute the calculated TDD as approximately 50% basal insulin and 50% nutritional (prandial) insulin 1. This means if you calculate a TDD of 40 units, give 20 units as basal insulin and divide the remaining 20 units across three meals.
Timing and Transition Strategy
The transition from IV to subcutaneous insulin requires careful timing to avoid rebound hyperglycemia:
Continue IV insulin infusion for 1-2 hours after administering the first subcutaneous insulin dose 2. This overlap is critical—abrupt discontinuation of IV insulin coupled with delayed onset of subcutaneous insulin leads to poor glycemic control 2.
Administer basal insulin (glargine or detemir) once daily at the same time each day 1.
Emerging Evidence on Early Basal Insulin
Recent research suggests potential benefits of initiating long-acting insulin earlier, even before complete DKA resolution. Studies show that starting subcutaneous glargine during the IV insulin phase (with ≥4 hours overlap) may reduce time to DKA resolution by 3-5 hours without increasing hypoglycemia risk 3. One study found that early glargine administration decreased insulin infusion duration and reduced rebound hyperglycemia, particularly in patients without type 1 diabetes 4. However, this approach is not yet incorporated into major guidelines and requires careful consideration of renal function 5.
Critical Caveats
Renal impairment requires dose reduction. Patients with acute kidney injury following DKA may experience prolonged insulin action and severe hypoglycemia, particularly with long-acting analogs like degludec 5. If initiating basal insulin during rising creatinine levels, consider using shorter-acting options or significantly reducing doses.
Type 1 diabetes patients require different management. These patients must receive basal insulin even when NPO, as they have absolute insulin deficiency 6. Never hold basal insulin in type 1 diabetes patients during care transitions.
Monitor closely after transition. Supplement with subcutaneous regular insulin every 4-6 hours as needed if the patient remains NPO after DKA resolution 2, 7. For eating patients, add rapid-acting insulin before meals in three equally divided doses 1.
Practical Example
For a 70 kg patient with blood glucose of 250 mg/dL at DKA resolution:
- Calculate TDD: 70 kg × 0.4 U/kg = 28 units/day
- Basal insulin dose: 28 × 0.5 = 14 units of glargine or detemir once daily
- Prandial insulin: Remaining 14 units divided as approximately 5 units before each meal
- Give first subcutaneous dose, then continue IV insulin for 1-2 hours before discontinuing